Eplontersen
New Drug Approvals
DECEMBER 24, 2023
1] It was developed to treat hereditary transthyretin amyloidosis by Ionis Pharmaceuticals and AstraZeneca. [2] 1] Society and culture Names Eplontersen is the international nonproprietary name. [9] Ionis Pharmaceuticals. 1] It is a transthyretin-directed antisense oligonucleotide. [1] twitter +919321316780 call whatsaapp EMAIL.
Let's personalize your content